Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs

Prostate

Volumn 69, Issue 13, 2009, Pages 1448-1459

  Sánchez, Catherine ^a   Mendoza, Patricia ^a   Contreras, Héctor R ^a   Vergara, Jorge ^a   McCubrey, James A ^b   Huidobro, Christian ^c   Castellón, Enrique A ^a,d  

^a UNIVERSITY OF CHILE   (Chile)

^b EAST CAROLINA UNIVERSITY   (United States)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Apoptosis; Chemotherapeutic drugs; Multidrug resistance proteins; Primary cell culture; Prostate cancer

Indexed keywords

DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EXPOSURE; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; TAXOIDS; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 69449088145     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20991     Document Type: Article

References (38)

1. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91(3):459-477.
2. Gonzalgo M, Isaacs W. Molecular pathways to prostate cancer. J Urol 2003;170:2444-2452.
3. American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
4. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 1997;15(1):382-388. (Pubitemid 27021526)
5. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39(1):41-51. (Pubitemid 46026500)
6. Ryan CJ, Small EJ. Advances in prostate cancer. Curr Opin Oncol 2004;16(3):242-246.
7. Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 2000;5(3):118-121. (Pubitemid 30182540)
8. Hernandez J, Thompson IM. Diagnosis and treatment of prostate cancer. Med Clin North Am 2004;88(2):267-279.
9. Beer TM, Bubalo JS. Prevention and management of prostate cancer chemotherapy complications. Urol Clin North Am 2004;31(2):367-378. (Pubitemid 38581229)
10. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512. (Pubitemid 39315317)
11. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84(1):265-269. (Pubitemid 17013615)
12. Kawai K, Sakurai M, Sakai T, Misaki M, Kusano I, Shiraishi T, Yatani R. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 2000;150:147-153. (Pubitemid 30125848)
13. Homma S, Komohara Y, Harada M, Saya H, Todo S, Itoh K, Noguchi M. Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: The robustness of prostate cancer. Oncol Rep 2007;18(2):343-346.
14. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998;4(6):1393-1403. (Pubitemid 28265221)
15. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, VanDer Kwast TH, Schröder FH, Mickisch GH. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001;165(1):130-135.
16. Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2003;51(4):297-305. (Pubitemid 36629807)
17. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999;35(4):664-671. (Pubitemid 29192979)
18. David-Beabes G, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-P R1: Characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol 2000;17(6):1077-1086.
19. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 2000;105(9):1261-1267. (Pubitemid 30266079)
20. van Brussel JP, Oomen MA, Vossebeld PJ, Wiemer EA, Sonneveld P, Mickisch GH. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: Chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine. BJU Int 2004;93(9):1333-1338. (Pubitemid 38823963)
21. Fedoruk MN, Giménez-Bonafe P, Guns ES, Mayer LD, Nelson CC. P-Glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate 2004;59(1):77-90. (Pubitemid 38387845)
22. Grzywacz MJ, Yang JM, Hait WN. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res 2003;63(10):2492- 2498. (Pubitemid 36605188)
23. Castellón E, Venegas K, Sáenz L, Contreras H, Huidobro C. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithetial-stromal co-cultures from human prostatic carcinoma. Int J Androl 2005;28(1):39-46. (Pubitemid 40203731)
24. Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 2006;24:261-268.
25. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Tumor necrosis factor-alpha and expression of the multidrug resistance- associated genes LRP and MRP. J Natl Cancer Inst 1997;89(11):807-813. (Pubitemid 27242283)
26. Valera ET, Scrideli CA, Queiroz RG, Mori BM, Tone LG. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 2004;122(4):166-171.
27. Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005;10(Suppl 3):30-39. (Pubitemid 43152728)
28. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23(15):3343-3345. (Pubitemid 46243478)
29. Yagüe E, Raguz S. Drug resistance in cancer. Br J Cancer 2005;93:973-976.
30. Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, Parkin JD. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 2000;3(2):66-75. (Pubitemid 30663591)
31. Effert PJ, McCoy RH, Walther PJ, Liu ET. p53 gene alterations in human prostate carcinoma. J Urol 1993;150(1):257-261. (Pubitemid 23176025)
32. Abolhoda A, Wilson A, Ross H, Danenberg P, Burt M, Scotto K. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999;5:3352-3356.
33. Hu XF, Slater A, Wall DM, Kantharidis P, Parkin JD, Cowman A, Zalcberg JR. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 1995;71(5):931-936.
34. Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, Lee G, Parkin JD, Zalcberg JR. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 1999;93(12):4086-4095. (Pubitemid 29279250)
35. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005;24(54):8061- 8075. (Pubitemid 41746749)
36. Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, Raguz S. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003;278(12):10344-10352. (Pubitemid 36800297)
37. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005;65(15):6934-6942. (Pubitemid 41060733)
38. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: Molecular regulation and therapeutic strategies. Blood 2004;104(7):1940-1951. (Pubitemid 39297842)